Polyiclc
Unresectable Malignant Solid Neoplasm
Mayo ClinicPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
58 Active assets in the Unresectable Malignant Solid Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Fred Hutchinson Cancer Center | Phase 2 | B |
Herzuma National Cancer Institute (NCI) | Phase 2 | B |
Talzenna National Cancer Institute (NCI) | Phase 2 | B |
Olaparib National Cancer Institute (NCI) | Phase 2 | B |
Bet Bromodomain Inhibitor Zen-3694 National Cancer Institute (NCI) | Phase 2 | B |
View all 50 →
Same molecule, other indications
Polyiclc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →